AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2023
Aug 11, 2023
31523_dirs_2023-08-11_fffa45d2-1823-4020-87d5-97b7ab349640.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2023-08-09
Reporting Person: Prout Samantha (Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-08-09 | Common Stock | M | 2376 | $10.04 | Acquired | 139379 | Direct |
| 2023-08-09 | Common Stock | M | 5040 | $9.55 | Acquired | 144419 | Direct |
| 2023-08-09 | Common Stock | M | 10592 | $10.03 | Acquired | 155011 | Direct |
| 2023-08-09 | Common Stock | M | 18901 | $12.11 | Acquired | 173912 | Direct |
| 2023-08-09 | Common Stock | S | 36909 | $14.0056 | Disposed | 137003 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-08-09 | Stock Options (right to buy) | $10.04 | M | 2376 | Disposed | 2029-01-02 | Common Stock (2376) | Direct |
| 2023-08-09 | Stock Options (right to buy) | $9.55 | M | 5040 | Disposed | 2030-01-02 | Common Stock (5040) | Direct |
| 2023-08-09 | Stock Options (right to buy) | $10.03 | M | 10592 | Disposed | 2030-04-15 | Common Stock (10592) | Direct |
| 2023-08-09 | Stock Options (right to buy) | $12.11 | M | 18901 | Disposed | 2032-01-14 | Common Stock (18901) | Direct |
Footnotes
F1: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.00 to $14.10 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: All of these options were fully vested and exercisable as of the transaction date.
F3: As of August 9, 2023, 5,985 options were fully vested and exercisable and 1,581 remained unvested from this individual 2020 grant.
F4: As of August 9, 2023, 11,164 options were fully vested and exercisable and 2,604 remained unvested from this individual 2020 grant.
F5: As of August 9, 2023, 22,444 options were fully vested and exercisable and 34,267 remained unvested from this individual 2022 grant.